Prevalence of drug-resistant tuberculosis in Sinaloa Mexico

Prevalence of rifampicin drug-resistant Mycobacterium tuberculosis in HIV and type 2 diabetic patients: A retrospective and cross-sectional study at endemic State Sinaloa Mexico

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN18957388

Enrollment

759

Registered

2022-08-10

Start date

2022-06-02

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevalence of drug-resistant Mycobacterium tuberculosis (DR-MTB) in HIV and diabetic patients Infections and Infestations

Interventions

Data will be analysed from SINAVE, which integrates information from all over the country and from all the institutions of the National Health System (SNS). The information generated by SINAVE, is rel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged between 18-85 years old 2. Populations with HIV or T2DM 3. Positive diagnosis in the state of Sinaloa in the period 2019-2021 of pulmonary Mycobacterium tuberculosis

Exclusion criteria

Exclusion criteria: 1. Aged 17 years old and under 2. Aged 86 years old and over 3. Extrapulmonary Mycobacterium tuberculosis diagnosis 4. Diagnosis in the other States of México 5. Diagnosis prior to 2019 or after 15 February 2022 6. Clinical cases HIV-TB and T2DM-TB not diagnosed with GeneXpert technique

Design outcomes

Primary

Measure	Time frame
Prevalence of rifampicin drug-resistant Mycobacterium tuberculosis, determined by a positive diagnosis using the GeneXpert MTB/RIF Dx System test version 4.7, recorded in the SINAVE database between January 2019 and February 2022	—

Secondary

Measure	Time frame
Recorded in the SINAVE database between January 2019 and February 2022: 1. Prevalence of TB/HIV, the following information will be used: p= number of events with the disease/total recorded events 2. Prevalence of TB/T2DM, the following information will be used: p= number of events with the disease/total recorded events 3. Prevalence of TB/T2DM drug resistance to rifampicin, the following information will be used: p= number of events with the disease/total recorded events 4. The correlation between suffering from the disease, HIV or T2DM with the presence of DR-TB, the prevalence ratio will be obtained and subsequently the prevalence odds ratio 5. Sociodemographic variables such as sex, age, weight, disease other than HIV or T2DM location of the disease, institution that provides care, the form of diagnosis, smoking, alcoholism and drug addiction will be recorded from the clinical history obtained from the SINAVE database	—

Measure

Time frame

Recorded in the SINAVE database between January 2019 and February 2022: 1. Prevalence of TB/HIV, the following information will be used: p= number of events with the disease/total recorded events 2. Prevalence of TB/T2DM, the following information will be used: p= number of events with the disease/total recorded events 3. Prevalence of TB/T2DM drug resistance to rifampicin, the following information will be used: p= number of events with the disease/total recorded events 4. The correlation between suffering from the disease, HIV or T2DM with the presence of DR-TB, the prevalence ratio will be obtained and subsequently the prevalence odds ratio 5. Sociodemographic variables such as sex, age, weight, disease other than HIV or T2DM location of the disease, institution that provides care, the form of diagnosis, smoking, alcoholism and drug addiction will be recorded from the clinical history obtained from the SINAVE database

—

Countries

Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026